Evidence map›Paper›PMID 40739043›Full record

ArticleDiscover oncology2025

Alterations in GSH/GSSG and CyS/CySS redox status in small cell lung cancer patients undergoing chemotherapy.

Azra Guzonjić, Milkica Crevar, Ivana Simić, Natalija Samardzić, Vesna Ćeriman Krstić, Jelena Kotur Stevuljević, Dragana Jovanović

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The effect of biogenic selenium nanoparticles (Frontiers in veterinary science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Azra GuzonjićFaculty of Pharmacy, Department for Medical Biochemistry, University of Belgrade, Vojvode Stepe 450, Belgrade, 11221, Serbia. azra.guzonjic@pharmacy.bg.ac.rs.
Milkica CrevarFaculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Belgrade, Vojvode Stepe 450, Belgrade, 11221, Serbia.
Ivana SimićMerck Sharp & Dohme d.o.o, Medical Affairs, Omladinskih brigada 90a, Belgrade, 11070, Serbia.
Natalija SamardzićClinic for pulmonology, University Clinical Center of Serbia, dr Koste Todorovica 26, Belgrade, 11000, Serbia.
Vesna Ćeriman KrstićClinic for pulmonology, University Clinical Center of Serbia, dr Koste Todorovica 26, Belgrade, 11000, Serbia.
Jelena Kotur StevuljevićFaculty of Pharmacy, Department for Medical Biochemistry, University of Belgrade, Vojvode Stepe 450, Belgrade, 11221, Serbia.
Dragana JovanovićInternal Medicine Clinic "Akta Medica", Cara Nikolaja II, Belgrade, 11000, Serbia.

Funding

The Ministry of Science, Technological Development and Innovation of the Republic of Serbia No. 451-03-65/2024-03/ 200161 and No. 451-03-66/2024-03/ 200161
6 · The paper itself

Abstract

backgroundIn small cell lung cancer (SCLC), oxidative stress disrupts redox balance and contributes to tumor progression and treatment resistance through DNA damage, inflammation, and tumorigenesis. Thiol compounds such as glutathione (GSH) and cysteine (CyS) together with their oxidized forms (GSSG and CySS) serve as markers of oxidative stress. The aim of this study was to investigate changes in GSH/GSSG and CyS/CySS ratios during chemotherapy and evaluate their potential as prognostic indicators in SCLC. MATERIALS AND

methodsIn this longitudinal study, redox biomarkers (GSH/GSSG and CyS/CySS ratios) were investigated in 60 stage III/IV SCLC patients receiving cisplatin-etoposide chemotherapy. Plasma samples were collected before chemotherapy, after two cycles and after four cycles and analyzed by LC-MS/MS.

resultsSignificant redox changes were observed during chemotherapy. The GSH/GSSG ratio decreased after two cycles (p = 0.029) and increased after four cycles (p = 0.002). The same trend was observed for CyS/CySS dynamics (p = 0.031 and p = 0.030, respectively). The Survivors showed a recovery of the redox balance, while the deceased patients showed persistently lower ratios. Kaplan-Meier analysis showed that a higher GSH/GSSG ratio before treatment (p = 0.037) predicted better survival. A positive correlation was found between GSH/GSSG and CyS/CySS ratios (ρ = 0.306, p = 0.019).

conclusionsThis study demonstrates that redox imbalance reflected in GSH/GSSG and CyS/CySS ratios is an important factor for SCLC treatment response and survival. Higher GSH/GSSG ratios before treatment are associated with improved survival, indicating the potential of redox markers as prognostic tools in SCLC.

Indexed as

Lung cancerOxidative stressPrognostic biomarkersRedox imbalance

Identifiers

PMID40739043
PMCPMC12311089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.